Literature DB >> 3785802

Ovarian cancer recurrences in patients with no macroscopic tumor at second-look laparotomy.

L J Copeland, D M Gershenson.   

Abstract

Second-look laparotomy has been relied upon extensively to guide the treatment of ovarian cancer. Among patients with other than well-differentiated primary tumors, the recurrence rate approximates 50% for patients with either negative or microscopically positive findings at second-look laparotomy. Although patients with persistent microscopic disease have received additional therapy, the patients with negative findings have not. The risk of recurrence seems high enough to consider adjuvant therapy for patients with negative findings at second-look laparotomy. However, since half of the patients remain disease free for an extended interval, and in view of the potential toxicity, any adjuvant treatment should be carried out by strict investigational protocol.

Entities:  

Mesh:

Year:  1986        PMID: 3785802

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

1.  The value of second-look operation in patients with advanced epithelial ovarian carcinoma.

Authors:  P Sevelda; C Dittrich; H Salzer
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 2.  The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.

Authors:  A E Selman; L J Copeland
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

3.  Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer.

Authors:  M O Nicoletto; R Padrini; H Koussis; A Rosabian; S Aversa; L Endrizzi; P Azzoni; M Palumbo; M V Fiorentino
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.

Authors:  A E Athanassiou; D Bafaloukos; D Pectasides; M Dimitriadis; I Varthalitis; V Barbounis
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

5.  Prognostic significance of ras/p21 alterations in human ovarian cancer.

Authors:  G Scambia; V Masciullo; P Benedetti Panici; M Marone; G Ferrandina; N Todaro; A Bellacosa; S K Jain; G Neri; A Piffanelli; S Mancuso
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.